Cleaved-SUMO2 (G93) Antibody

What is SUMO2/3 and what biological functions does it serve?

SUMO2/3 (Small Ubiquitin-Related Modifier 2/3) is a ubiquitin-like protein that can be covalently attached to target proteins as a monomer or as a lysine-linked polymer through a process called SUMOylation. This post-translational modification plays crucial roles in numerous cellular processes, including nuclear transport, DNA replication and repair, mitosis, and signal transduction. The covalent attachment occurs via an isopeptide bond and requires activation by the E1 complex SAE1-SAE2, linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2, CBX4, or ZNF451 . Polymeric SUMO2 chains can undergo polyubiquitination, which serves as a signal for proteasomal degradation of modified proteins. SUMO2 also plays a specific role in regulating the sumoylation status of SETX (senataxin). Within cells, SUMO2/3 is predominantly located in the nucleus, particularly in PML bodies, and is broadly expressed across various tissues .

What is the Cleaved-SUMO2/3 (G93) Antibody and how does it differ from other SUMO antibodies?

The Cleaved-SUMO2/3 (G93) Antibody is a rabbit polyclonal antibody specifically designed to recognize the cleaved form of SUMO2/3 at the glycine 93 position. This antibody binds to the endogenous Small Ubiquitin-Related Modifier 2 at the amino acid region 20-100 internal . Unlike antibodies that target the full-length SUMO2/3, this antibody specifically recognizes the cleaved form, making it valuable for studying SUMO processing and mature SUMO conjugates. The specificity of this antibody allows researchers to distinguish between precursor and mature forms of SUMO2/3, providing insights into the dynamics of SUMO processing and conjugation in various cellular contexts . The antibody has been validated for use in Western blot and ELISA applications, with recommended dilutions of 1:500-1:2000 for Western blots and 1:20000 for ELISA .

What are the optimal conditions for using Cleaved-SUMO2/3 (G93) Antibody in Western blot analyses?

For optimal Western blot results with Cleaved-SUMO2/3 (G93) Antibody, researchers should adhere to specific protocol considerations. The recommended dilution range is 1:500-1:2000 for Western blot applications . Sample preparation is critical—cells or tissues should be lysed in denaturing conditions with SUMO protease inhibitors (such as N-ethylmaleimide or iodoacetamide) to prevent desumoylation during processing. When running SDS-PAGE, use 10-12% gels to effectively resolve SUMO conjugates, which typically appear as higher molecular weight bands compared to the target protein alone. For the transfer step, use PVDF membranes rather than nitrocellulose for better protein retention. Blocking should be performed with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature. After primary antibody incubation (preferably overnight at 4°C), wash thoroughly with TBST before adding HRP-conjugated secondary antibody. For validation, include appropriate positive controls such as HeLa cell lysates, which have been confirmed to express SUMO2/3 conjugates detectable by this antibody . The antibody is stored in PBS containing 50% glycerol, 0.5% BSA, and 0.09% sodium azide and should be kept at -20°C for long-term storage .

How can researchers effectively validate the specificity of Cleaved-SUMO2/3 (G93) Antibody in their experimental systems?

Validating the specificity of Cleaved-SUMO2/3 (G93) Antibody requires multiple complementary approaches. First, researchers should perform peptide competition assays, where the antibody is pre-incubated with the immunizing peptide before Western blotting. As demonstrated in the product validation data, this should block specific signals, confirming antibody specificity . Second, use positive and negative control samples—cell lines known to express high levels of SUMO2/3 conjugates (e.g., HeLa cells) versus those with SUMO2/3 knockdown or knockout. Third, compare staining patterns with other validated SUMO2/3 antibodies targeting different epitopes. Fourth, employ immunoprecipitation followed by mass spectrometry to identify pulled-down proteins and confirm they are known SUMO2/3 substrates. For advanced validation, researchers can use CRISPR/Cas9-engineered cell lines with mutations in the SUMO2/3 sequence at the antibody recognition site. Additionally, overexpression of SUMO2/3 should enhance signal intensity, while RNA interference-mediated knockdown should reduce it. These combined approaches provide comprehensive validation of antibody specificity across different experimental conditions .

What are the considerations for using Cleaved-SUMO2/3 (G93) Antibody in cell-based ELISA applications?

When implementing cell-based ELISA with Cleaved-SUMO2/3 (G93) Antibody, several methodological considerations are essential for successful outcomes. The antibody has been specifically validated for cell-based colorimetric ELISA applications with a recommended dilution of 1:20000 . For optimal results, cells should be cultured in 96-well plates until they reach 80-90% confluency before fixation. When fixing cells, use 4% paraformaldehyde for 15-20 minutes at room temperature to preserve protein structure while maintaining cell morphology. For permeabilization, 0.1-0.2% Triton X-100 in PBS for 10 minutes is recommended to allow antibody access to intracellular antigens. The blocking solution should contain 5% BSA in PBS to minimize non-specific binding. After primary antibody incubation, use HRP-conjugated secondary antibodies and suitable chromogenic substrates for detection. A critical aspect of cell-based ELISAs is normalization—crystal violet staining for total cell number quantification helps account for well-to-well variations in cell density . This approach enables relative quantification of SUMO2/3-conjugated proteins across different experimental conditions, providing a high-throughput alternative to traditional Western blot analysis for studying SUMOylation dynamics in intact cells.

How can researchers effectively design experiments to study dynamics of SUMO2/3 conjugation under different cellular conditions?

Designing experiments to study SUMO2/3 conjugation dynamics requires careful consideration of multiple factors. First, establish appropriate time points for analysis—SUMOylation can be rapidly induced within minutes of stimulation, necessitating short-interval time course studies. Second, incorporate relevant cellular stressors known to affect SUMOylation, such as heat shock, oxidative stress, or genotoxic agents. Third, use protein synthesis inhibitors like cycloheximide to distinguish between de novo SUMOylation and changes in protein expression levels. Fourth, employ SUMO protease inhibitors (N-ethylmaleimide or iodoacetamide) in lysis buffers to preserve SUMOylation status post-extraction. For more sophisticated analyses, incorporate SUMO site-specific mutants of target proteins to validate conjugation sites and their functional significance. Combination approaches using both the Cleaved-SUMO2/3 (G93) Antibody and antibodies against specific target proteins can help track SUMOylation of individual substrates. For in vivo studies, consider using tagged SUMO models such as the His6-HA-Sumo2 mouse line, which has been validated for studying SUMOylation patterns in various tissues . Finally, parallel assessment of ubiquitination status can provide insights into cross-talk between these post-translational modification pathways, particularly for SUMO2/3 which can form chains susceptible to polyubiquitination and subsequent proteasomal degradation .

How can researchers differentiate between SUMO1 and SUMO2/3 modification of target proteins in complex samples?

Differentiating between SUMO1 and SUMO2/3 modification of target proteins requires sophisticated experimental approaches. The most direct method employs paralog-specific antibodies, such as the Cleaved-SUMO2/3 (G93) Antibody for SUMO2/3 and equivalent SUMO1-specific antibodies, in parallel Western blots or immunoprecipitations. For more definitive analysis, researchers can utilize engineered mouse models expressing tagged versions of SUMO paralogs, such as the His6-HA-Sumo1 and His6-HA-Sumo2 lines described in the literature . These models enable selective purification and identification of SUMO1 versus SUMO2/3 conjugates through tandem affinity purification protocols. Mass spectrometry-based approaches following immunoprecipitation can identify specific SUMO attachment sites and distinguish between paralogs based on remnant peptides after tryptic digestion. Cell-based assays overexpressing one SUMO paralog at a time, coupled with substrate-specific antibodies, can also reveal preferential modification patterns. Additionally, stress-response experiments can help distinguish between SUMO1 and SUMO2/3 targets, as SUMO2/3 conjugation often shows more dramatic changes under stress conditions, while SUMO1 modification tends to be more constitutive . When interpreting results, researchers should consider the possibility of mixed SUMO chains or sequential modification by different SUMO paralogs on the same substrate.

What are the challenges in detecting endogenous SUMO2/3 conjugates and how can they be overcome?

Detecting endogenous SUMO2/3 conjugates presents several significant challenges. First, the typically low abundance of SUMOylated forms of most target proteins (often <5% of the total protein pool) makes detection difficult. To overcome this, researchers should use enrichment strategies prior to detection, such as immunoprecipitation with the Cleaved-SUMO2/3 (G93) Antibody or nickel-affinity purification in systems expressing His-tagged SUMO2/3 . Second, the dynamic nature of SUMOylation, which is rapidly reversed by SUMO proteases, necessitates immediate sample processing with SUMO protease inhibitors (20-25 mM N-ethylmaleimide) in lysis buffers. Third, the presence of SUMO-targeted ubiquitin ligases can lead to rapid degradation of SUMO2/3-modified proteins; using proteasome inhibitors (MG132) in conjunction with SUMO protease inhibitors can help preserve these conjugates. Fourth, the large size and heterogeneity of SUMO chains can cause diffuse bands on Western blots; using gradient gels (4-15%) can improve resolution. For tissues with high SUMO protease activity, denaturing lysis conditions and immediate boiling of samples are recommended. Alternative approaches include using cell-based ELISA methods for quantifying total SUMO2/3 conjugates , or developing targeted mass spectrometry assays for specific SUMO2/3 substrates of interest.

How can researchers identify novel SUMO2/3 target proteins using Cleaved-SUMO2/3 (G93) Antibody?

Identifying novel SUMO2/3 target proteins requires a strategic multi-step approach. Immunoprecipitation with Cleaved-SUMO2/3 (G93) Antibody followed by mass spectrometry analysis represents a powerful starting point. This approach has been validated in studies using His6-HA-Sumo2 mouse models, which successfully identified both highly SUMOylated proteins and those modified at lower levels, such as Matrin3 (Matr3) . For improved sensitivity, researchers can implement a SUMO remnant immunoaffinity profiling strategy, where samples are trypsin-digested after immunoprecipitation, generating peptides with characteristic SUMO remnants that can be enriched with remnant-specific antibodies. Comparative proteomic analysis between control and treatment conditions (e.g., stress, differentiation) can reveal condition-specific SUMO2/3 targets. Bioinformatic approaches combining experimental data with SUMO-site prediction algorithms enhance target identification by prioritizing proteins with high-confidence SUMO consensus motifs (ψKxE). To validate candidate targets, researchers should perform reciprocal immunoprecipitations with antibodies against the target protein followed by Cleaved-SUMO2/3 (G93) Western blotting. Site-directed mutagenesis of predicted SUMO attachment lysines to arginine can confirm specific modification sites. For in vivo studies, leveraging mouse models with tagged SUMO2, such as the His6-HA-Sumo2 line, provides a powerful system for identifying physiologically relevant SUMO2/3 substrates in different tissues and developmental stages .

What approaches can be used to study the crosstalk between SUMO2/3 modification and other post-translational modifications?

Studying the crosstalk between SUMO2/3 and other post-translational modifications (PTMs) requires integrated experimental designs. Sequential immunoprecipitation represents a powerful approach—first precipitate with Cleaved-SUMO2/3 (G93) Antibody, then with antibodies against other PTMs (e.g., phospho-specific, acetylation-specific) to identify dually modified proteins. Mass spectrometry-based multi-PTM analyses can simultaneously detect SUMO2/3, ubiquitin, phosphorylation, and acetylation on the same protein, providing a comprehensive PTM landscape. Temporal studies examining the order of modification events help establish causal relationships between different PTMs—do phosphorylation events precede or follow SUMOylation? CRISPR/Cas9-generated cell lines expressing PTM-site mutants of specific target proteins can determine whether one modification is prerequisite for another. For studying SUMO2/3-ubiquitin crosstalk specifically, utilize proteasome inhibitors while monitoring changes in both modifications, as SUMO2/3 chains can be targeted by SUMO-targeted ubiquitin ligases (STUbLs) for subsequent degradation . Proximity ligation assays provide in situ visualization of proteins simultaneously modified by SUMO2/3 and other PTMs without disrupting cellular architecture. Advanced computational approaches integrating experimentally identified PTM sites with structural data can predict how different modifications might sterically influence each other. To validate functional consequences, compare the activities of proteins bearing different combinations of PTMs through in vitro enzymatic assays or cellular phenotype rescue experiments.

What quality control steps should researchers implement when working with Cleaved-SUMO2/3 (G93) Antibody?

Implementing rigorous quality control is essential when working with Cleaved-SUMO2/3 (G93) Antibody. First, validate each new antibody lot against previous lots using standard positive control samples (such as HeLa cell lysates) in Western blot applications . Second, include peptide competition controls where the antibody is pre-incubated with the immunizing peptide to confirm signal specificity. Third, incorporate both positive and negative biological controls—cell lines known to express SUMO2/3 conjugates versus those with SUMO2/3 knockdown. Fourth, run parallel blots with multiple SUMO2/3 antibodies targeting different epitopes to corroborate findings. Fifth, verify antibody performance across different techniques (Western blot, immunoprecipitation, ELISA) before employing it in complex experimental designs . Sixth, maintain proper storage conditions (-20°C in aliquots to avoid freeze-thaw cycles) and track antibody performance over time to identify potential degradation. Seventh, include recombinant SUMO2/3 protein standards in Western blots to establish detection sensitivity limits. Eighth, document all antibody information (catalog number, lot number, dilution) in research records to ensure reproducibility. When troubleshooting unexpected results, systematically evaluate all experimental variables, including sample preparation methods, buffer compositions, and detection reagents, before concluding that observed phenotypes are biologically relevant rather than technical artifacts.

How do storage conditions and handling procedures affect Cleaved-SUMO2/3 (G93) Antibody performance?

The performance of Cleaved-SUMO2/3 (G93) Antibody is significantly influenced by proper storage and handling. According to manufacturer specifications, the antibody should be stored at -20°C in its supplied format—PBS containing 50% glycerol, 0.5% BSA, and 0.09% sodium azide . Repeated freeze-thaw cycles can substantially degrade antibody quality through protein denaturation and aggregation; therefore, preparing small working aliquots upon receipt is strongly recommended. The recommended storage buffer components serve specific functions: glycerol prevents freezing-induced denaturation, BSA stabilizes antibody molecules and prevents non-specific adsorption to container surfaces, while sodium azide prevents microbial contamination. When preparing working dilutions, use fresh buffer components and maintain cold chain practices by keeping the antibody on ice during experiment setup. Extended storage of diluted antibody solutions should be avoided, as this can lead to reduced binding capacity and increased background. For long-term storage beyond one year, consider lyophilization or storage at -80°C with cryoprotectants. Temperature fluctuations during shipping or improper laboratory storage can lead to gradual loss of activity over time; therefore, performing regular quality control tests on aged antibody preparations is advisable. If diminished performance is observed, titration experiments with fresh antibody lots can help re-establish optimal working concentrations for different applications.

What are the most common pitfalls in SUMO2/3 detection experiments and how can they be avoided?

SUMO2/3 detection experiments are prone to several common pitfalls that can compromise data quality. First, inadequate inhibition of SUMO proteases during sample preparation leads to rapid deconjugation; this can be addressed by including 20-25 mM N-ethylmaleimide in lysis buffers and processing samples quickly at cold temperatures. Second, high background on Western blots often results from insufficient blocking or excessive primary antibody concentration; optimize blocking conditions (5% BSA or milk) and titrate the Cleaved-SUMO2/3 (G93) Antibody to find the minimum effective concentration (typically 1:500-1:2000) . Third, failure to detect low-abundance SUMO conjugates can be overcome by employing enrichment strategies like immunoprecipitation or using systems with tagged SUMO2/3 . Fourth, misinterpretation of bands can occur when SUMO-modified proteins co-migrate with non-specific signals; conduct appropriate controls including peptide competition and SUMO2/3 knockdown samples. Fifth, inconsistent results between experiments often stem from variations in cell confluency and stress conditions; standardize culture conditions and minimize environmental stressors that can alter SUMOylation patterns. Sixth, cross-reactivity with other ubiquitin-like modifiers can confound interpretation; validate findings with multiple antibodies and complementary approaches. Seventh, cell lysis methods significantly impact SUMOylation detection; harsh denaturing conditions (8M urea or 1% SDS) best preserve SUMO conjugates but may interfere with immunoprecipitation protocols requiring native conditions. Finally, quantification challenges arise from the heterogeneous nature of SUMO conjugates; use cell-based ELISA approaches or specialized image analysis software capable of quantifying smeared signals in addition to discrete bands.

What are the considerations for developing multiplexed assays involving SUMO2/3 detection alongside other protein modifications?

Developing multiplexed assays for simultaneous detection of SUMO2/3 and other protein modifications requires careful experimental design. First, antibody compatibility is crucial—select primary antibodies from different host species (e.g., rabbit anti-Cleaved-SUMO2/3 with mouse anti-phospho-protein) to enable selective secondary antibody detection. For fluorescence-based multiplex Western blots, choose fluorophores with minimal spectral overlap and control for potential bleed-through using single-labeled controls. When detecting modifications on the same target protein, consider sequential immunoprecipitation approaches—first pull down with substrate-specific antibodies, then probe for modifications, or vice versa. For imaging-based assays, proximity ligation techniques can visualize proteins bearing multiple modifications simultaneously within intact cells, providing spatial information about modified protein subpopulations. Mass spectrometry-based approaches offer the most comprehensive solution, capable of detecting multiple PTMs on the same peptide, though they require specialized equipment and expertise. When designing multiplexed assays, account for potential epitope masking effects where one modification might interfere with antibody recognition of another nearby modification. For quantitative analyses, develop appropriate normalization strategies for each modification type (e.g., normalizing SUMO2/3 signals to total protein while normalizing phosphorylation to total target protein). Finally, validation with single-modification controls and known biological stimuli that differentially affect various modifications is essential to ensure assay specificity and sensitivity.

How are CRISPR/Cas9 approaches being integrated with SUMO2/3 research using antibody-based detection methods?

CRISPR/Cas9 technology is revolutionizing SUMO2/3 research when integrated with antibody-based detection systems. Researchers are generating knock-in cell lines expressing endogenously tagged SUMO2/3 (similar to the His6-HA-Sumo2 mouse models) using CRISPR/Cas9-mediated homology-directed repair, enabling detection with highly specific anti-tag antibodies while maintaining physiological expression levels . This approach parallels the successful generation of tagged Sumo2 mouse lines where CRISPR/Cas9 was used to introduce His6-HA tags at the amino-terminus of the endogenous Sumo2 gene . CRISPR/Cas9 is also being employed to create cell lines with mutations in specific SUMO target proteins to validate antibody specificity and study functional consequences of SUMOylation. Genome-wide CRISPR screens combined with Cleaved-SUMO2/3 (G93) Antibody-based detection are identifying novel regulators of the SUMO conjugation/deconjugation machinery. For more precise temporal control, researchers are developing inducible CRISPR systems to conditionally manipulate SUMO pathway components, followed by antibody-based detection of resulting changes in global SUMOylation patterns. Advanced applications include creating cellular models where endogenous SUMO2/3 is replaced with mutant versions that cannot form chains or be cleaved by specific proteases, providing powerful tools for mechanistic studies when combined with the Cleaved-SUMO2/3 (G93) Antibody. These approaches significantly enhance our ability to study SUMOylation dynamics under physiologically relevant conditions.

What are the recent advances in using Cleaved-SUMO2/3 (G93) Antibody for tissue-specific SUMOylation profiling?

Recent advances in tissue-specific SUMOylation profiling using Cleaved-SUMO2/3 (G93) Antibody have expanded our understanding of SUMO2/3 function in different physiological contexts. Research using His6-HA-Sumo2 mouse models has demonstrated the feasibility of characterizing tissue-specific SUMOylation landscapes through immunoprecipitation followed by mass spectrometry . This approach has revealed tissue-specific SUMO2/3 targets and conjugation patterns that vary significantly between different organs and cell types. Technological developments in tissue clearing and multiplexed immunofluorescence now enable three-dimensional visualization of SUMO2/3-modified proteins within intact tissue architectures. Laser capture microdissection combined with Cleaved-SUMO2/3 (G93) Antibody-based detection allows analysis of SUMOylation patterns in specific cell populations within heterogeneous tissues. For developmental studies, temporal profiling of SUMO2/3 modification during organ formation has identified stage-specific SUMOylation events critical for proper morphogenesis. Advances in single-cell proteomic approaches are beginning to reveal cell-to-cell variation in SUMOylation profiles within tissues. Pathology-focused applications have employed the antibody to compare SUMOylation patterns between healthy and diseased tissues, identifying disease-specific alterations that may represent therapeutic targets. Tissue microarray technology in conjunction with automated image analysis now enables high-throughput screening of SUMO2/3 modification levels across hundreds of patient samples simultaneously. These methodological advances collectively provide unprecedented insights into the tissue-specific roles of SUMO2/3 in both physiological and pathological states.

How might new proteomics approaches enhance the utility of Cleaved-SUMO2/3 (G93) Antibody for studying the SUMOylome?

Emerging proteomics approaches are dramatically enhancing the utility of Cleaved-SUMO2/3 (G93) Antibody for comprehensive SUMOylome analysis. Technical innovations in targeted proteomics, such as parallel reaction monitoring (PRM) and selected reaction monitoring (SRM), now enable quantification of specific SUMO2/3-modified peptides with unprecedented sensitivity, overcoming traditional challenges in detecting low-abundance SUMO conjugates. Integration of antibody-based enrichment with advanced mass spectrometry techniques like data-independent acquisition (DIA) provides both deeper coverage and more accurate quantification of the SUMOylome. Crosslinking mass spectrometry (XL-MS) combined with Cleaved-SUMO2/3 (G93) immunoprecipitation can reveal structural insights into how SUMO2/3 modification affects protein-protein interactions and complex formation. Developments in top-down proteomics now enable analysis of intact SUMO-modified proteins, preserving information about combinations of modifications that may be lost in traditional bottom-up approaches. Novel SUMO remnant enrichment strategies, inspired by ubiquitin remnant profiling, are being developed to directly identify SUMO2/3 attachment sites with higher confidence. Proximity-dependent labeling approaches (BioID, APEX) combined with SUMO2/3 antibody-based purification can map the spatial organization of SUMOylation machinery and substrates within different cellular compartments. Thermal proteome profiling techniques integrated with SUMO2/3 enrichment can reveal how SUMOylation affects protein thermal stability, providing functional insights. These methodological advances significantly enhance our ability to characterize the dynamic SUMO2/3 proteome with unprecedented depth, accuracy, and contextual information.

What are the implications of studying SUMO2/3 dynamics for understanding disease mechanisms and developing therapeutics?

The study of SUMO2/3 dynamics has profound implications for understanding disease mechanisms and developing novel therapeutics. Aberrant SUMOylation has been implicated in numerous pathological conditions, including cancer, neurodegenerative disorders, and cardiovascular diseases. Using Cleaved-SUMO2/3 (G93) Antibody for comparative profiling of normal versus diseased tissues has identified disease-associated changes in SUMOylation patterns that could serve as diagnostic biomarkers or therapeutic targets . In cancer biology, SUMO2/3 modification regulates the activity of key oncoproteins and tumor suppressors, with altered SUMOylation contributing to malignant transformation and therapeutic resistance. For neurodegenerative conditions like Alzheimer's and Parkinson's diseases, accumulating evidence indicates that dysregulated SUMO2/3 conjugation affects protein aggregation and neuronal stress responses. Small molecule inhibitors targeting specific components of the SUMO conjugation machinery are being developed as potential therapeutics, with their efficacy assessable through antibody-based detection of global SUMOylation changes. CRISPR-based approaches for modulating SUMOylation of specific disease-relevant targets represent another promising therapeutic avenue. The development of cell-penetrating SUMO-targeted chimeric molecules that direct specific proteins for SUMOylation or deSUMOylation offers a novel approach to modulating protein function in disease contexts. Patient-derived organoids combined with Cleaved-SUMO2/3 (G93) Antibody-based analysis provide platforms for personalized medicine approaches targeting SUMOylation. These multifaceted approaches underscore the potential of targeting SUMO2/3 dynamics for therapeutic intervention across diverse pathological conditions.